Umecrine Cognition获得23.8M瑞典克朗的贷款,用于对新的PBC治疗进行临床试验。 Umecrine Cognition secures a SEK 23.8M loan for a clinical trial of a new PBC treatment.

瑞典一家生物制药公司Umecrine Cognition已获得2,380万瑞典克朗的可兑换贷款,以资助其目前正在进行的治疗初级口服炎(PBC)的口服高血激素临床试验。 Umecrine Cognition, a Swedish biopharmaceutical company, has secured a SEK 23.8 million convertible loan to fund its ongoing clinical trial of golexanolone for treating primary biliary cholangitis (PBC). 包括Karolinska Development、AB Iliity和Ribbskottet AB在内的投资者提供的资金将支付这项研究明年的费用和业务开支。 The funding, from investors including Karolinska Development, AB Ility, and Ribbskottet AB, will cover the study’s costs and operational expenses for next year. 预计将于2025年上半年结束的这一试验已显示出可喜的成果,该药物在初步阶段获得良好许可并有效。 The trial, expected to finish in the first half of 2025, has shown promising results with the drug being well-tolerated and effective in preliminary stages.